As part of its development strategy in the healthcare sector, Dislog Group announces the signature of a memorandum of understanding for the acquisition of 70% of the capital of Afrobiomedic, a leading player in specialized cardiology medical devices.
This operation is in line with our ambition to structure a national champion for medical devices and actively contribute to improving the healthcare sector in Morocco, by making cutting-edge medical technologies more accessible. Afrobiomedic brings recognized expertise in interventional and structural cardiology, rhythmology and vascular neuroradiology.
Afrobiomedic joins our healthcare division, alongside Megaflex, Kosmopharm, Steripharma, SomaPharma, Africare and Dislog Santé, as part of an industrial integration strategy covering the entire value chain.
"We believe in the potential for industrial, human and operational synergies around a common project focused on innovation and impact," emphasizes the CEO. Moncef Belkhayat, President of Dislog Group.
Special thanks to Driss NASR, founder and sole shareholder of Afrobiomedic, who retains 30% of the capital and will continue to manage the company to support its growth.